NCT04447274 is a Phase 2 clinical trial of Camrelizumab and Apatinib in Sarcoma, sponsored by Chinese Academy of Medical Sciences.

Who is sponsoring NCT04447274?

NCT04447274 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT04447274?

Interventions in NCT04447274: Camrelizumab and Apatinib.

Is NCT04447274 still recruiting?

NCT04447274 is currently status unknown. Last updated 25 June 2020.

Last reviewed 2020-06-25 · How we verify

NCT04447274

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Status unknown Phase 2 Last updated 25 June 2020

What this trial tests

Phase 2 trial testing Camrelizumab and Apatinib in Sarcoma in 20 participants. Status unknown.

Timeline

1 July 2020

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 July 2020
Primary completion	31 December 2021
Estimated completion	31 December 2021

Drugs / interventions tested

Camrelizumab and Apatinib — full drug profile →

Conditions studied

Sarcoma — all drugs for Sarcoma →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

16 and older, any sex, with Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study ,Target population is Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma (UPS) and Alveolar Soft Tissue Sarcoma (ASPS) . The purpose of this study was to evaluate the safety and efficacy of combination of Camrelizumab and Apatinib in the treatment of unresectable UPS and ASPS

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov.
Que Y, Hu Y, Hong D, Zhang Y. · · 2021 · cited 11× · PMID 34583971 · DOI 10.1136/jitc-2021-002920
Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors.
Fleuren EDG, Terry RL, Meyran D, Omer N, et al · · 2021 · cited 9× · PMID 34944614 · DOI 10.3390/biomedicines9121798
Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series.
Tan H, Wang H, Zhou J, Jiang L, et al · · 2026 · PMID 42051923 · DOI 10.2147/tcrm.s586907
Genetic Heterogeneity of Undifferentiated Pleomorphic Sarcoma: Is There Potential for Targeted Therapy?
Lesovaya EA, Fetisov TI, Bokhyan BY, Senchenko MA, et al · · 2025 · PMID 41300979 · DOI 10.3390/cancers17223613

Verify or expand the search:

Other trials of Camrelizumab and Apatinib

Trials testing the same drug.

NCT04612894 — Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer · Phase 2 · unknown

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04447274 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 25 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04447274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing